PHR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q4

FY2027Q1

FY2027Q2

126.84M

+15.64%

0.056

-150.67%

135.49M

+16.86%

0.092

-231.74%

136.63M

+16.52%

0.116

+1055.6%

Estimates Revision

The market is revising Upward the revenue expectations for Phreesia, Inc. (PHR) for FY2026, with the revenue forecasts being adjusted by 0.68% over the past three months. During the same period, the stock price has changed by -27.73%.

Revenue Estimates for FY2026

Revise Upward

+0.68%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-309.01%

In Past 3 Month

Stock Price

Go Down

-27.73%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast PHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHR is 34.10 USD with a low forecast of 32.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

12 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

32.00

Averages

34.10

High

38.00

Current: 0.000

Low

32.00

Averages

34.10

High

38.00

Truist

Buy

downgrade

$29 -> $24

2026-01-08

New

Reason

Truist

Price Target

$29 -> $24

2026-01-08

New

downgrade

Buy

Reason

Truist lowered the firm's price target on Phreesia to $24 from $29 and keeps a Buy rating on the shares. Shares underperformed in 2025 despite the company executing on its strategy to prioritize earnings power over growth, and investor skepticism around sustainable top-line growth persists, the analyst tells investors in a research note. Truist says Phreesia is now a "show me" story for 2026, needing several quarters of revenue and EBITDA outperformance to regain investor confidence.

Wells Fargo

Stan Berenshteyn

Overweight

initiated

$30

2026-01-08

New

Reason

Wells Fargo

Stan Berenshteyn

Price Target

$30

2026-01-08

New

initiated

Overweight

Reason

Wells Fargo analyst Stan Berenshteyn initiated coverage of Phreesia with an Overweight rating and $30 price target. The company owns intake, scheduling, and payments across 14% of U.S. patient visits, the analyst tells investors in a research note. The firm views Phreesia as a "stock to own," saying it trades below its 2019 initial offering price price despite nearly quadrupling revenue. The stock's valuation is "no longer an overhang," add Wells.

Barclays

Overweight

downgrade

$26 -> $24

2025-12-16

Reason

Barclays

Price Target

$26 -> $24

2025-12-16

downgrade

Overweight

Reason

Barclays lowered the firm's price target on Phreesia to $24 from $26 and keeps an Overweight rating on the shares. The firm updated the company's model to reflect the Q3 results and OneAccess closing. It views the recent selloff in the shares as surprising.

Baird

Outperform -> NULL

downgrade

$31 -> $25

2025-12-10

Reason

Baird

Price Target

$31 -> $25

2025-12-10

downgrade

Outperform -> NULL

Reason

Baird lowered the firm's price target on Phreesia to $25 from $31 and keeps an Outperform rating on the shares. The firm updated its mdoel to rflect the company's latest guidance for 2026-2027.

Mizuho

Steven Valiquette

Outperform

NULL

downgrade

$36 -> $28

2025-12-10

Reason

Mizuho

Steven Valiquette

Price Target

$36 -> $28

2025-12-10

downgrade

Outperform

NULL

Reason

Mizuho analyst Steven Valiquette lowered the firm's price target on Phreesia to $28 from $36 and keeps an Outperform rating on the shares. Shares fell 22% after management struck a more cautious tone on Q4 Network Solutions revenue, citing softer Pharma digital marketing sentiment amid political pressures, the analyst tells investors in a research note. While FY27 growth may slow to roughly the low-teens, management's outlook appears conservative, Mizuho adds.

Truist

Buy

maintain

$36 -> $29

2025-12-10

Reason

Truist

Price Target

$36 -> $29

2025-12-10

maintain

Buy

Reason

Truist lowered the firm's price target on Phreesia to $29 from $36 and keeps a Buy rating on the shares after the firm had a post-quarter call with the company's management to discuss its FY26 and FY27 expectations, AccessOne, Trends in the average number of healthcare services clients, among other topics. Truist notes Phreesia posted solid Q3 results, with in-line revenues and adjusted EBITDA ahead of consensus, updated its FY26 outlook, and introduced its FY27 guidance. The firm points out that the organic growth slowdown was attributed to revenue guide approach shift, and says fundamentals remain intact.

Valuation Metrics

The current forward P/E ratio for Phreesia Inc (PHR.N) is 39.95, compared to its 5-year average forward P/E of -34.48. For a more detailed relative valuation and DCF analysis to assess Phreesia Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-34.48

Current PE

39.95

Overvalued PE

94.49

Undervalued PE

-163.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-34.44

Current EV/EBITDA

7.14

Overvalued EV/EBITDA

86.34

Undervalued EV/EBITDA

-155.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.68

Current PS

1.83

Overvalued PS

10.01

Undervalued PS

1.36

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PHR News & Events

Events Timeline

No data

News

3.0

2025-12-22Barron's

Phreesia Shares Have Plummeted, But We Maintain Our Recommendation.

3.5

2025-12-18Newsfilter

Phreesia Ranked Top 10 in Software Report's 2025 Software Companies List for Fourth Consecutive Year

2.0

2025-12-09Yahoo Finance

Reasons Behind Phreesia's 23% Stock Decline Today

People Also Watch

Frequently Asked Questions

What is Phreesia Inc (PHR) stock price today?

The current price of PHR is 17.23 USD — it has increased 1.95 % in the last trading day.

What is Phreesia Inc (PHR)'s business?

Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.

What is the price predicton of PHR Stock?

What is Phreesia Inc (PHR)'s revenue for the last quarter?

Phreesia Inc revenue for the last quarter amounts to 120.33M USD, increased 12.67 % YoY.

What is Phreesia Inc (PHR)'s earnings per share (EPS) for the last quarter?

Phreesia Inc. EPS for the last quarter amounts to 0.07 USD, decreased -128.00 % YoY.

What changes have occurred in the market's expectations for Phreesia Inc (PHR)'s fundamentals?

How many employees does Phreesia Inc (PHR). have?

Phreesia Inc (PHR) has 2082 emplpoyees as of January 10 2026.

What is Phreesia Inc (PHR) market cap?

Today PHR has the market capitalization of 1.04B USD.